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Abstract:  Colon cancer is the third leading cause of cancer-related deaths worldwide. 
Recent studies in our laboratory have demonstrated that arsenic trioxide is cytotoxic in 
human colon cancer (HT-29), lung (A549) and breast (MCF-7) carcinoma cells. The 
purpose of the present study is to investigate the effects of arsenic trioxide on DNA 
synthesis and the possible genotoxic effects on human colon cancer cells. HT-29 cells were 
cultured according to standard protocol, followed by exposure to various doses (0, 2, 4, 6, 
8, 10, and 12 μg/mL) of arsenic trioxide for 24 h. The proliferative response (DNA 
synthesis) to arsenic trioxide was assessed by [
3H]thymidine incorporation. The genotoxic 
effects of arsenic-induced DNA damage in a human colon cancer cell line was evaluated 
by the alkaline single cell gel electrophoresis. Results indicated that arsenic trioxide 
affected DNA synthesis in HT-29 cells in a biphasic manner; showing a slight but not 
significant increase in cell proliferation at lower levels of exposure (2, 4 and 6 µg/mL) 
OPEN ACCESSInt. J. Environ. Res. Public Health 2010, 7          
 
 
2019
followed by a significant inhibition of cell proliferation at higher doses (i.e., 8 and 10 
µg/mL). The study also confirmed that arsenic trioxide exposure caused genotoxicity as 
revealed by the significant increase in DNA damage, comet tail-lengths, and tail moment 
when compared to non-exposed cells. Results of the [
3H]thymidine incorporation assay and 
comet assay revealed that exposure to arsenic trioxide affected DNA synthesis and 
exhibited genotoxic effects in human colon cancer cells. 
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1. Introduction 
Colon cancer is defined as any malignant neoplasm arising from the inner lining of the colonic 
epithelium, and is the third most common cancer and the leading cause of cancer related deaths for 
both men and women in the United States [1]. The majority of colon cancers are benign lesions 
(adenomas) that can develop into malignant tumors that span an average of 15–20 years. Colon cancer 
begins in the epithelial tissue of the colon, and the cancer spreads to nearby lymph nodes and other 
parts of the body during advance stages of development [1]. Early detection and yearly check-ups are 
known to reduce the risk of dying of colon cancer. Individuals with colon cancer can receive treatment 
and possibly be cured if the polyps are detected before the polyps become cancerous or finding the 
cancer at an early stage.  
 Arsenic is a well known human toxicant and carcinogenic metalloid. Exposure to arsenic and its 
compounds can have adverse effects on human health [2]. Epidemiological studies based on ingestion 
of arsenic have been implicated in noncarcinogenic health effects in various organs and systems 
including cardiovascular, dermal, reproductive, neurological, respiratory, hepatic, hematological, 
renal, and gastrointestinal [2]. Nonetheless, exposure to arsenic has been associated with the 
development of malignancies, severe gastrointestinal toxicities, diabetes, cardiovascular diseases, and 
even death. The relationship of arsenic and malignancy is a major concern. It has been documented 
that long-term arsenic exposure is associated with increased risks of numerous human cancers [2,3], 
and as a result, arsenic has been classified as a human carcinogen by both the U.S. Environmental 
Protection  
Agency [4] and the IARC [5]. Exposure to arsenic orally or by inhalation can lead to increased risk of 
skin and lung cancer respectively [4]. In addition to lung cancer, cancers of the liver, kidney, lung, 
colon and bladder are affected with increased arsenic exposure [4,6,7]. The mechanism of action of 
arsenic in carcinogenesis has not been clearly elucidated [3,4]. Many mechanisms have been 
implicated for arsenic-induced carcinogenesis, such as genotoxicity, induction of oxidative stress and 
DNA damage, inhibition of DNA repair enzymes involved in nucleotide excision repair and base 
excision repair, tumor promotion, cell proliferation, chromosomal aberrations, and signal transduction 
or altered DNA methylation [8-12]. There is no ideal animal model to study arsenic-induced cancers Int. J. Environ. Res. Public Health 2010, 7          
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observed in humans, therefore investigations using human cell lines and affected individuals in 
exposed areas are ongoing.  
  Arsenic toxicity has become a global public health concern and has affected human health. 
Numerous epidemiological studies have reported that large populations in the world are being exposed 
chronically to arsenic [4]. Exposure to inorganic arsenic occurs via environmental (e.g., contaminated 
drinking water, air, food, domestic fuel sources) and occupational exposures (e.g., smelting industries, 
pesticide production). The toxicity of arsenic is very complicated and the toxicity varies on its 
oxidative state and solubility [4,13,14]. The trivalent compounds such as arsenic trioxide, sodium 
arsenite and arsenite, and arsenic trichloride are more toxic than the pentavalent compounds such as 
arsenic pentoxide, arsenic acid, lead and calcium arsenates [4,13]. The trivalent and pentavalent forms 
of arsenic are found in arsenic-contaminated water [13,15]. This metalloid affects a variety of tissues 
and cells depending on the degree of exposure. Acute or chronic exposure has been reported in several 
countries around the world due to the high concentrations found in drinking water [6,16-19]. The 
increased cancer risk posed by contaminated water is thought to be due to the presence of inorganic 
trivalent arsenite [20]. The impairment of cellular respiration by the inhibition of various 
mitochondrial enzymes, and the uncoupling of oxidative phosphorylation is believed to be one of the 
mechanisms by which arsenic exerts is toxic effect [4]. Arsenic toxicity is thought to result from its 
ability to interact with sulfhydryl groups of proteins and enzymes, and to substitute phosphoruous in a 
variety of biochemical reactions [4,14]. Research has shown that the major metabolic pathway for 
inorganic arsenic in humans is methylation in which most of the inorganic arsenic is metabolized to 
monomethylarsonic acid and dimethylarsinic acid before excretion in the urine [4]. There is still much 
discussion as to whether arsenic is a carcinogen by itself or acts synergistically to predispose cells to 
transformation by complete carcinogens [10].  
Tests for genotoxicity have indicated that arsenic compounds inhibit DNA repair, induce 
chromosomal aberrations, and sister chromatid exchanges [4,21-23] Genotoxic effects of arsenic have 
been reported in various cell lines and rodents [24-26]. Studies have shown that arsenic acts through a 
series of chemical reactions in the cell, interacting strongly with nearby molecules, and changing the 
structure of cellular components such as DNA [24]. Arsenic does not induce genetic mutations in most 
test systems, but chromosomal damage has been reported in cultured mammalian cells, possibly as a 
result of arsenic’s effects on the enzymes involved in DNA replication and repair. Arsenic has been 
implicated in promoting alterations in growth and proliferation pathways, apoptotic pathways, DNA 
repair mechanisms, and stress-response pathways [27-29]. Some studies have reported that the 
generation of DNA damage includes DNA strand breaks [30]. Recent studies have provided evidence 
that arsenite
  can induce DNA damage by promoting the formation of reactive
  oxygen species 
particularly superoxide radical anions and hydrogen
 peroxide [8-9]. Arsenical compounds have also 
been shown to induce gene amplification, arrest cells in mitosis, and inhibit gene repair [4,31]. The 
mechanism of genotoxicity is not known, but it may be due to the ability of arsenate to inhibit DNA, 
replicating or repair enzymes [6,32].  
 Arsenic compounds have been used in a variety of beneficial applications. These compounds have 
been used in industry for the production of paints and glass and are components of semiconductors. In 
addition, arsenic compounds are also used to manufacture products with agricultural applications such 
as insecticides, fertilizers, weed kills, fungicides, and wood preservatives [6]. Arsenic has a long Int. J. Environ. Res. Public Health 2010, 7          
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history of usage as a medicinal. Many arsenic-containing compounds have been used for treatment of 
human diseases such as syphilis, amoebic dysentery, African sleeping sickness, and Hodgkin’s 
lymphoma [4,33]. Although arsenic trioxide (As2O3) is highly toxic, this compound has been shown to 
have therapeutic potential. Inorganic arsenic trioxide has been clinically approved for the treatment of 
several hematological malignancies [33]. Studies have shown that arsenic trioxide has antitumor 
properties and has been approved by the Food and Drug Administration (FDA) for the treatment of 
promyelocytic leukemia in humans [34,35]. In addition, As2O3 has been shown to inhibit proliferation, 
induce apoptosis, and inhibit angiogenesis in multiple myeloma cells in vitro and in vivo [36]. Some 
studies have suggested that As2O3 may have activity in the treatment of some solid tumor such as lung 
cancer, breast cancer, esophageal carcinoma, ovarian, and gastric cancer. Studies have investigated the 
anti-vascular effect of As2O3 and the potential of combining As2O3  with radiation therapy [37]. 
Significant benefits of arsenic trioxide have been reported, which further improved the outcome of 
patients with these malignancies.  
 There is no ideal treatment for colon cancer. One of the primary issues for cancer chemotherapy is 
how to kill cancer cells selectively without damaging normal cells. Arsenic trioxide may be useful in 
combination therapy. It has been reported that the combination therapy of As2O3 with   
L-buthionine-sulfoximine enhanced in vitro growth inhibition effect of As2O3 on prostate, breast, lung, 
colon, cervix, bladder, and kidney cancers compared with As2O3 alone [38]. The aim of this present 
study was to use human colon cancer (HT-29) cells as an in vitro test model to evaluate the potential 
therapeutic action of arsenic trioxide against colon cancer. We hypothesized that As2O3 is cytotoxic to 
HT-29 cells and its cytotoxicity is associated with DNA damage in cancer cells.  
 
2. Materials and Methods 
 
Reagents and Cell Line 
 
Human colon cancer (HT-29) cells were purchased from American Type Culture Collection 
(ATCC) (Manassa, VA). Arsenic trioxide with 99.9% purity was purchased from Fisher Scientific 
(Houston, TX). McCoy’s 5A growth medium, and 0.4% trypan blue were purchased from ATCC 
(Manassas, VA). Fetal bovine serum (FBS), penicillin/streptomycin, phosphate buffered saline (PBS), 
and 0.25% trypsin-EDTA (w/v) were purchased from Gibco (Grand Island, NY). [
3H 
methyl]Thymidine was obtained from MP Biomedicals (Irvine, CA). CometAssay
TM kit was purchased 
from Trevigen, Inc (Gaithersburg, MD). 
 
Cell Culture 
 
HT-29 cells were maintained in complete growth medium (CGM) [McCoy’s 5A medium 
supplemented with 10% FBS and 1% antibiotics (penicillin/streptomycin)]. HT-29 cells   
(1 × 10
6 cells/mL) were plated in T-25 flasks containing 5 mL of CGM and grown in a humidified 
incubator under an atmosphere of 95% air and 5% CO2 at 37 ºC to sub-confluence (90–95%). The 
culture medium was replaced every 48 h. Once the cells reached 90–95% confluency, the medium was 
aspirated, and the cell monolayer was washed three times with sterile phosphate buffered saline. The Int. J. Environ. Res. Public Health 2010, 7          
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cell monolayer was treated with 1 mL of 0.25% (w/v) trypsin-EDTA and incubated briefly at 37 ºC 
and visualized microscopically to ensure complete cell detachment. Cells were re-suspended in 
McCoy’s 5A complete growth medium. For experimental purposes, cells were stained with trypan 
blue, incubated for 2 min at room temperature, and counted using a hemacytometer. Cells were seeded 
on  
13 × 100 mm tissue culture plates at a density of 1 × 10
5 cells/plate prior to arsenic trioxide treatment. 
 
[
3H]Thymidine Incorporation Assay 
 
Incorporation of [
3H]thymidine into newly synthesized DNA was used as a measure of cell 
proliferation. Cells were seeded in 6-well tissue culture plates at a density of 5 × 10
5 cells/well in CGM 
and grown at 37 ºC in a 5% CO2 humidified incubator until cells were 60%–70% confluent.   
Sub-confluent cells were incubated overnight in McCoy’s 5A medium supplemented with 1% fetal 
bovine serum and 1% antibiotics (penicillin/streptomycin) prior to treatment. Cells were treated with 
different doses of arsenic trioxide (0, 2, 4, 6, 8, 10, and 12 µg/mL) in CGM. The control (0 µg/mL) 
received complete growth medium only. Cells were incubated for 18 h before 1µCi/mL [
3H 
methyl]thymidine was added to each well for an additional 6 h period to measure the incorporation of 
[
3H methyl] thymidine into the DNA. The incubation of tritiated thymidine was terminated by 
aspirating the culture medium and followed by three washes of cold phosphate buffered saline pH 7.4. 
In addition, 2 mL of ice cold 10% trichloroacetic acid (TCA) was added to each well and incubated for 
20 min at 4 
oC. The TCA was aspirated and the cells were washed three times with ice-cold water. 
After the washing, the cells were solubilized with 1 mL of 0.5 M NaOH/well at 37 
oC for 30 min. 
[
3H]Thymidine incorporation was quantitated in a scintillation counter (Beckman Instruments). Each 
treatment group was assayed in triplicates, and each experiment was repeated at least three times.  
  
Genotoxicity Study 
 
Comet assay kit was used according to the instructions of the manufacturer (Trevigen Inc, 
Gaithersburg, MD). HT-29 cells were seeded at 3 × 10
5 per plate and placed at 37 ºC in a 5% CO2 
humidified incubator until 70% confluency. The CGM was removed, and the sub-confluent cells were 
incubated overnight in McCoy’s 5A medium supplemented with 1% FBS and 1% antibiotics 
(penicillin/streptomycin) for 24 h prior to treatment. Cells incubated in CGM served as a control for 
DNA damage (untreated cells). Cells were treated with different doses of As2O3 (0, 2, 4, 6, 8, 10, and 
12 µg/mL) for 24 h in complete growth medium. Following the As2O3 treatments, the medium was 
removed, and the cells were washed three times with cold PBS, trypsinized with 1 mL of 0.25% 
trypsin-EDTA, harvested, and counted. The cells were spun down at 3000 rpm for 5 min. The pellet 
was re-suspended in PBS at a cell density of 1 × 10
5. The cells were combined with molten 
LMAgarose (at 37 ºC) at a ratio of 1:10 (v/v), and 75 µL was immediately pipetted onto 
CometSlide
TM. The slides were placed flat in a refrigerator at 4 °C for 30 min, and then immersed in 
prechilled lysis solution on ice for 1 h. Excess buffer from slides was removed, and the slides were 
immersed in freshly prepared alkaline solution, pH > 13 (0.6 g of NaOH pellets, 250 µL of 200 mM 
EDTA and 49.75 mL of dH2O) for 1 h. Slides were washed twice for 5 min with 1X TBE Int. J. Environ. Res. Public Health 2010, 7          
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electrophoresis buffer (Tris base, boric acid, and EDTA) and electrophoresed in a horizontal gel 
apparatus at 1 V/cm (22 V) for 10 min. Slides were placed in 70% ethanol for 5 min, removed, and 
tapped to remove excess ethanol. Slides were air dried overnight, stained with SYBR Green, and 
allowed to set for 12 h. Photographs were taken to illustrate the changes in DNA morphology 
associated with arsenic trioxide exposure. For examining SYBR Green stained comet slides, a total of 
150 comets were scored per arsenic trioxide dose. Seventy-five comets were randomly selected from 
three replicated slides, viewed with an Olympus Epifluorescence Microscope, and analyzed using the 
LAI’s Automated Comet Assay Analysis System (LACAAS) (Loates Associates, Inc. Westminister, 
MD). The experiment was repeated at least three times.  
  
Statistical Analysis 
 
[
3H]Thymidine Incorporation Assay 
 
Experimental data were represented as means ± SEMs since each experiment was repeated three 
times. Statistical analysis was performed uising SAS software (SAS Institute, Cary, NC) for Microsoft 
Windows. The Dunnett’s test was used to determine statistical differences in DNA synthesis between 
control and arsenic trioxide-treated HT-29 cells. Multiple comparisons were done by ANOVA. All  
P-values < 0.05 were considered to be significant.  
 
Genotoxicity Study 
 
Data generated from the Comet assay were analyzed using the LAI’s Automated Comet Assay 
Analysis System (LACAAS) that provided the mean values and standard deviations of percent DNA 
damage, tail length, and tail moment. Similar to the DNA incorporation data, ANOVA was applied for 
global comparison followed by Dunnett’s test for identifying groups whose means were significantly 
different from the control. 
 
3. Results 
 
[
3H]Thymidine Incorporation Assay 
 
Data obtained from the [
3H]thymidine incorporation assay exhibited a biphasic response to arsenic 
trioxide in the colon cancer cells. The results showed a slight but not significant increase in cell 
proliferation at lower levels of exposure (2, 4 and 6 µg/mL) followed by a significant inhibition of cell 
proliferation at higher doses (i.e., 8 and 10 µg/mL) relative to the controls (Figure 1). The change in 
[
3H]thymidine uptake and DNA incorporation was statistically significant at 8 and 10 µg/mL. Int. J. Environ. Res. Public Health 2010, 7          
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Figure 1. [
3H]thymidine incorporation assay of HT-29 cells after 24 h exposure to arsenic 
trioxide. Cell proliferation was determined by measuring the [
3H]thymidine incorporation 
(cpm) into DNA. Data are represented as mean ± SEM of three separate experiments 
performed in triplicates. Statistical analysis was done using the SAS software system. 
Differences were considered statistically significant with a P value < 0.05 according to the 
Dunnett’s test. The significance of the value is indicated by asterisks (*).  
 
 
Genotoxicity Study 
 
The comet assay permits quantitative assessment of the effects of DNA damage or apoptosis. The 
applications of the comet assay include analysis of genotoxic activity, human, and environmental 
biomonitoring to DNA repair processes, cellular response to DNA damage, chromosomal damage, 
cancer risk assessment, and cancer cell resistance to treatment [39]. The genotoxic effect of arsenic 
trioxide was investigated in colon cancer (HT-29) cells. Figure 2 is the representative picture of comet 
images displaying the cell DNA migration patterns by the alkaline comet assay for HT-29 cells treated 
with arsenic trioxide for 24 h. As shown in this figure, the nuclear DNA of untreated cells is perfectly 
round and retains a highly organized association with matrix proteins in the nucleus. The nuclear DNA 
of arsenic-treated cells is severely fragmented as the dosage increases and the organization is 
disrupted. The individual strands of DNA lose their compact structure and relax and DNA fragments 
(damage) are observed. The extent of DNA damage was determined by measuring the tail moment, the 
percent of DNA fragmentation (percent of DNA in the comet tail versus total DNA), and the length of 
the comet tail. The higher the percent of DNA fragments and tail moment, the more severe is the 
damage. Similarly, the brighter and longer the comet tail, the higher the level of damage.  Int. J. Environ. Res. Public Health 2010, 7          
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Figure 2. Representative comet assay images depicting the genotoxic effect of arsenic 
trioxide-treated (A = 0 µg/mL, B = 2 µg/mL, C = 4 µg/mL, D = 6 µg/mL, E = 8 µg/mL,  
F = 10 µg/mL, and G = 12 µg/mL) colon cancer cells exposed for 24 h using SYBR
®  
green staining. 
 
 
The comet assay revealed that treatment of colon cells with arsenic trioxide caused severe damage 
to the cells. Results of the visual scoring of tail moment, the length of the comet tails, and total DNA 
damage are shown in Figure 3. The HT-29 cells were treated with 0–12 µg/mL of arsenic trioxide for 
24 h, which resulted in an increase in tail moment in the treated cells compared with the control. DNA 
damage was significant as indicated by the increased tail moment, tail length, and the percentage of 
DNA fragmentation observed in the treated cells compared with the control. As a result, the DNA 
damage induced by the arsenic trioxide was dose-dependent. Int. J. Environ. Res. Public Health 2010, 7          
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Figure 3. Arsenic trioxide-induced DNA damage as characterized by the increase in tail 
moment, the percentage of DNA damage, and the length of comet tails in colon cancer 
(HT-29) cells. Cells were exposed to arsenic trioxide for 24 h, and the comet assay was 
performed as described in the Materials and Methods section. Data were expressed as 
means ± SDs. Differences were considered statistically significant at P < 0.05 according to 
the Dunnett’s test.  
 
 
4. Discussion 
 
Colorectal cancer is one of the most commonly diagnosed cancers in the United States and is 
responsible for about 53,000 deaths. Great strides have been made in the treatment of colon cancer. It 
has been well documented that the environmental contaminant, inorganic arsenic, is a human toxicant 
and carcinogen. Epidemiological studies have demonstrated that chronic arsenic exposure causes 
tumors of the skin, urinary bladder, lung, liver, prostate, kidney, and colon [10,11]. Studies in arsenic 
carcinogenesis were first reported in cases of skin cancer after exposure to inorganic arsenic in 
drinking water [11,12]. Hwang et al. have shown that low levels of arsenic exposure predispose cells 
for malignant transformation [40]. Several potential mechanisms have been suggested such as 
induction of oxidative stress and DNA damage, stimulation of cell proliferation, inhibition of DNA 
repair, and deregulation of DNA methylation in arsenic-induced carcinogenesis [28,29]. However, the 
mechanism(s) underlying its carcinogenicity remains unclear. Arsenic has cytotoxic effects on several 
cancer cell lines. Reported studies in our laboratory have shown that As2O3 induces cytotoxicity in a 
dose-dependent manner in HT-29 cells [41]. Tchounwou et al. revealed a dose-response in human liver 
carcinoma cells (HepG2) [42] and human leukemia cells (HL-60) when exposed to arsenic   
toxicity [43]. It has been reported that As2O3 induced clinical remission in patients with acute 
promyelocytic leukemia and other malignancies. 
Historically, cell proliferation assays relied on the detection of tritiated thymidine [
3H] uptake. The 
thymidine incorporation assay measures the inhibition of deoxyribonucleic acid (DNA) synthesis by Int. J. Environ. Res. Public Health 2010, 7          
 
 
2027
the proliferating cell population following exposure to a drug or chemical. In the present study, we 
demonstrated that arsenic trioxide affected DNA synthesis in colon cancer cells (HT-29). Data 
obtained from the [
3H]thymidine incorporation assay exhibited a biphasic response to arsenic trioxide 
in the colon cancer cells. The data from this study reveals that arsenic trioxide inhibits cellular 
proliferation at higher doses (i.e., 8 and 10 µg/mL). This result is consistent with preliminary studies in 
our laboratory that revealed a biphasic response to arsenic trioxide in the breast carcinoma (MCF-7) 
cell line. Studies have shown that arsenic trioxide is acutely toxic to both breast carcinoma (MCF-7) 
and lung carcinoma (A549) cell lines [44]. Arsenic trioxide has been shown to significantly enhance 
growth inhibition in human breast cancer MCF-7 cells determined by the MTT   
[3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide] assay and [
3H]thymidine incorporation 
assay [45]. Hamadeh et al. demonstrated that the incorporation of [
3H]thymidine was markedly 
increased, relative to the control levels in arsenite-exposed keratinocytes indicating an increase in cell 
proliferation [46]. Germolac et al. reported that human keratinocytes, treated with sodium arsenite 
resulted in a significant increase in cell proliferation as indicated by the incorporation of 
[
3H]thymidine into cellular DNA [47]. Trouba et al. reported an increase in cell proliferation observed 
in human fibroblasts exposed to sodium arsenite [48]. Lee et al. showed that arsenic trioxide alone 
slightly inhibited the growth of HCT116 colon cancer cells, whereas the combination of arsenic 
trioxide and sulindac reduced cell growth by 30–40% [49]. Data in this study reveal that arsenic 
trioxide increases cellular proliferation in human colon cancer cells as measured by [
3H]thymidine 
incorporation. These observations confirm the effects of arsenic on cell proliferation in keratinocytes, 
fibroblasts, human breast (MCF-7), and HCT116 colon cancer cells.  
The comet assay, also known as single gel electrophoresis, is a visual and sensitive method used to 
measure single-strand (ss) DNA breaks or DNA cleavage in mammalian cells [30]. Any DNA damage 
is represented as a tail length (tail migration) of the DNA strand. The overall structure resembles a 
comet with a circular head corresponding to the undamaged DNA that remains in the cavity and a tail 
of damaged DNA. The damage usually detected by the comet assay is single-strand breaks and double 
strand breaks [50]. Arsenic has been shown to induce DNA damage in human cells. In our present 
study, we have observed molecular changes in HT-29 cells. DNA damage induced by arsenic trioxide 
in colon cancer cells was determined by alkaline comet assay. The cells exhibited a high degree of 
DNA damage after 24 h treatment as shown by the increase in tail moment, tail length, and percentage 
of DNA damage observed in the treated cells compared to the controls. There was a dose-dependent 
increase in the tail moment, tail length, and the percentage of DNA in the tail. The increase in DNA 
fragmentation is thought to lead to increase in apoptosis in cells treated with arsenic trioxide. Our 
studies are consistent with previous findings in that the increase in arsenic results in an increase in the 
level of DNA damage.  
Studies have shown that arsenic trioxide is highly cytotoxic and genotoxic to human leukemia  
(HL-60) cells. These studies using the comet assay showed that arsenic trioxide induced DNA damage 
in a dose-dependent manner [43]. Graham et al. showed that arsenic was highly genotoxic to human 
keratinocytes, melanocytes, and dendritic cells [25]. The data showed a statistically significant   
dose-related increase in percentage of tail DNA. Studies have shown that arsenic-induced DNA 
damage in human hepatocytes measured by the comet assay [51]. Genotoxic studies have reported that 
arsenic trioxide induces DNA damage in lymphocytes [4]. Guillamet et al. have reported DNA damage Int. J. Environ. Res. Public Health 2010, 7          
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in the human lymphobastoid cell line (TK6) by the alkaline Comet assay [52]. Several studies have 
implicated oxidative stress and free radical
 formation as important factors in the genotoxicity and 
cytotoxicity
 of arsenic compounds [8,9]. Arsenic trioxide exerts its effects mainly through elevated 
oxidative stress, but the exact molecular mechanism remains elusive. Reactive oxygen species (ROS) 
such as hydrogen peroxide, superoxide anion, singlet oxygen, and hydroxyl radical can directly or 
indirectly damage cellular DNA and protein [9].  
 
5. Conclusions 
 
Human exposure to arsenic, a toxic environmental pollutant, is associated with an increased 
incidence of human cancers. Epidemiologic studies have long supported a link between human 
exposure to inorganic arsenic and an increased incidence of cancers, which have led to intensive 
investigations of the underlying mechanism. However, the precise molecular and cellular mechanism 
by which arsenic causes cancer has not yet been established. These studies have implicated a number 
of mechanisms such as induction of oxidative stress and DNA damage, stimulation of cell 
proliferation, inhibition of DNA repair, and deregulation of DNA methylation in arsenic-induced   
carcinogenesis [14,15]. Our data suggest that As2O3 can significantly affect proliferation in HT-29 
cells. This research is also the first to report investigating the in vitro effects of DNA damage in human 
colon cancer (HT-29) cells. The approach of using the comet assay is very sensitive to detect genetic 
damage in the cells. It is expected that these data in this study will serve as a foundation for furthering 
our knowledge of the effects of arsenic trioxide on human colon cancer cells and will contribute to a 
better understanding of arsenic-based chemotherapy. 
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